← Back to screener

Cartesian Therapeutics, Inc. RNAC

Rank #2136 · Nasdaq · $0.2B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
32.5
P/E
-2.5
P/B
-0.43
ROE
17.6%
Op. Margin
-112.8%
Debt Ratio
-100%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -2.5x, P/B -0.43x. Ranks in the top 98% of the universe.

Profitability ★★☆☆☆
Average

ROE 17.6%. Ranks in the top 58% of the universe.

Safety ★★★★★
Excellent

Debt ratio -100%. Ranks in the top 6% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 49.6% year over year. Ranks in the top 7% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2016$0.0B$-0.0B$-0.0B$-0.1B-506.5-31
2017$0.0B$-0.0B$-0.0B$-0.1B-421.0-39
2018$0.0B$-0.0B$-0.0B$-0.1B-428.9-42
2019$0.0B$-0.1B$-0.1B$0.1B-30813.591
2020$0.0B$-0.1B$-0.1B$0.1B-7200.7176
2021$0.0B$-0.1B$-0.1B$-0.0B-785.6-3386
2022$0.0B$-0.1B$-0.1B$0.0B-342.41636
2023$0.1B$-0.0B$-0.0B$-0.0B-5.4-400
2024$0.0B$-0.1B$-0.2B$0.1B-332.3474
2025$0.0B$-0.0B$-0.1B$-0.4B-112.8-100

← See the full screener